top of page

Sala sławy

These are the clinical trials currently available in the UK in respect of ALK-positive lung cancer.

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (USZ-STRIKE)

A Study of NVL-655 (new ALK TKI targeting ALK and resistance mutations) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Nuvalent Trial

More Information

Lorlatinib Activity Based on ALK Resistance Mutations Detected on Blood (ALKALINE)

Lorlatinib with ALK-Positive NSCLC
(which has progressed on first-line certinib or alectinib)

Alectinib: Deciphering anti tumor response and resistance
with intratumor heterogenicity
(Darwin II)

Navigational Bronchoscopy for ablation of tumours in the lung - a trial at the Royal Brompton.

Go to details for a press report

A trial to ascertain whether presribing an anticoagulant together with a TKI will reduce the incidence of blood clots. (NOMADIC

UK Trials that are no longer recruiting new patients

RAMON -

A study looking at further treatment after initial treatment for advanced non small cell lung cancer.

HALT -

A trial of stereotactic body radiotherapy with targeted drug treatment in advanced non small lung cancer

World-Wide Studies and Trials

ALK+ Trials/Studies

ALK Positive (USA) Research Library

Studies/Reports of Interest

Cancer Vaccines

Where are we?

CRUK

Alectinib after surgery at Stages I-III

FDA approved

April 2024

A summary of vaccine studies in the UK

Funding approved for a vaccine study in the UK

Local Therapy for

Oligo-progression

CROWN Study

Lorlatinib as 1st line treatment

ALK Life Study

A longitudinal study being carried out by ALK Positive Inc (USA)

Anyone with lungs can get lung cancer.

bottom of page